Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Profit After Tax (2022 - 2025)

Historic Profit After Tax for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$44.1 million.

  • Entrada Therapeutics' Profit After Tax fell 21452.39% to -$44.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.5 million, marking a year-over-year decrease of 28826.77%. This contributed to the annual value of $65.6 million for FY2024, which is 108169.04% up from last year.
  • According to the latest figures from Q3 2025, Entrada Therapeutics' Profit After Tax is -$44.1 million, which was down 21452.39% from -$43.1 million recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Profit After Tax high stood at $55.0 million for Q2 2024, and its period low was -$44.1 million during Q3 2025.
  • Its 4-year average for Profit After Tax is -$9.4 million, with a median of -$17.3 million in 2025.
  • In the last 5 years, Entrada Therapeutics' Profit After Tax surged by 45205.27% in 2024 and then plummeted by 21452.39% in 2025.
  • Entrada Therapeutics' Profit After Tax (Quarter) stood at -$24.6 million in 2022, then skyrocketed by 61.25% to -$9.5 million in 2023, then surged by 111.85% to $1.1 million in 2024, then crashed by 4002.21% to -$44.1 million in 2025.
  • Its last three reported values are -$44.1 million in Q3 2025, -$43.1 million for Q2 2025, and -$17.3 million during Q1 2025.